Source comparison
2. Molecular structure — full-length GHRH vs CJC-1295
Tesamorelin is [trans-3-hexenoyl]-hGHRH(1-44)-NH₂ — the 44-amino-acid native human GHRH sequence with a trans-3-hexenoyl (a C6 unsaturated acyl) group attached to the N-terminal tyrosine. Molecular weight 5196.00 Da. The hexenoyl group blocks DPP-4 cleavage at
This comparison does not assign a generated winner or score.
- Tesamorelin is [trans-3-hexenoyl]-hGHRH(1-44)-NH₂ — the 44-amino-acid native human GHRH sequence with a trans-3-hexenoyl (a C6 unsaturated acyl) group attached to the N-terminal tyrosine. Molecular weight 5196.00 Da. The hexenoyl group blocks DPP-4 cleavage at position 2 (Ala), which would otherwise be the primary inactivation pathway.
- Comparison with other GHRH analogues:
- Sermorelin: GHRH(1-29), unmodified, 29 aa. Half-life 10-20 min. No longer widely used.
- CJC-1295 no-DAC: GHRH(1-29) with 4 aa substitutions. Half-life 25-30 min. Preserves pulsatility; supersedes sermorelin.
- CJC-1295 with DAC: Same as no-DAC plus maleimido-lysine tail for albumin conjugation. Half-life ~8 days as albumin conjugate. Tonic activation.
- Tesamorelin: Full-length GHRH(1-44) with hexenoyl N-terminal modification. Half-life ~30-40 min (plasma); biological effect duration 3-4 hours.
- The key structural distinction: tesamorelin retains the full C-terminal domain (aa 30-44), which is absent from all CJC-1295 variants. The full-length structure may interact with additional GHRH receptor binding determinants that the 1-29 fragment does not engage, contributing to tesamorelin’s distinctive visceral-fat effect.